[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_NoncurrentFinancialAssetSaleAbstract|
Non-Current Financial Asset Sale
oda_UpdateAnnouncementFlag|
Update Notification Flag
Evet (Yes)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
27.10.2020 ; 31.10.2017 ; 11.09.2017 ; 18.08.2017
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_BoardDecisionDateForSale|
Board Decision Date for Sale
02/11/2021
oda_WereMajorityOfIndependentBoardMembersApprovedTheBoardDecisionForSale|
Were Majority of Independent Board Members' Approved the Board Decision for Sale?
Yes
oda_TitleOfNoncurrentFinancialAssetSold|
Title of Non-current Financial Asset Sold
Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş.
oda_FieldOfActivityNoncurrentFinancialAssetSold|
Field of Activity of Non-current Financial Asset Sold
In the health sector, it operates in the fields of manufacture, import and distribution of radiopharmaceuticals used in nuclear medicine.
oda_CapitalOfNoncurrentFinancialAssetSold|
Capital of Non-current Financial Asset Sold
TL 67,500,000
oda_DateOnWhichRheTransactionWasWillBeCompleted|
Date on which the Transaction was/will be Completed
02/11/2021
oda_SalesConditions|
Sales Conditions
Peşin (Cash)
oda_NominalValueOfSharesSold|
Nominal Value of Shares Sold
TL 2,025,000
oda_SalesPricePerShare|
Sales Price Per Share
TL 4.95 (*)
oda_TotalSalesValue|
Total Sales Value
TL 10,015,709.96 (*)
oda_RatioOfSharesSoldToCapitalOfNoncurrentFinancialAsset|
Ratio of Shares Sold to Capital of Non-current Financial Asset (%)
3.00
oda_TotalRatioOfSharesOwnedInCapitalOfNoncurrentFinancialAssetAfterSalesTransaction|
Total Ratio of Shares Owned in Capital of Non-current Financial Asset After Sales Transaction (%)
78
oda_TotalVotingRightRatioOwnedInNoncurrentFinancialAssetAfterSalesTransaction|
Total Voting Right Ratio Owned in Non-current Financial Asset After Sales Transaction (%)
78
oda_RatioOfNoncurrentFinancialAssetSoldToTotalAssetsInLatestDisclosedFinancialStatementsOfCompany|
Ratio of Non-current Financial Asset Sold to Total Assets in Latest Disclosed Financial Statements of Company (%)
0.02
oda_RatioOfTransactionValueToSalesInLatestAnnualFinancialStatementsOfCompany|
Ratio of Transaction Value to Sales in Latest Annual Financial Statements of Company (%)
1.1
oda_EffectsOnCompanyOperations|
Effects on Company Operations
None.
oda_ProfitLossArisedAfterTransaction|
Profit / Loss Arised After Transaction
TL 8,855,620.16 profit (Consolide IFRS) (*)
oda_HowWillSalesProfitBeUsedIfExists|
How will Sales Profit be Used if Exists?
75% of share sales profit 5 of the corporate tax code No. 5520. Article 1. it will be kept in a private fund account for the purpose of benefiting from the exception specified in paragraph (e) of paragraph.
oda_BoardDecisionDateForUseOfSalesProfitIfExists|
Board Decision Date for Use of Sales Profit if Exists
02/11/2021
oda_TitleNameSurnameOfCounterPartyBought|
Title/ Name-Surname of Counter Party Bought
Şükrü Bozluolçay and Uğur Bozluolçay
oda_IsCounterPartyARelatedPartyAccordingToCMBRegulations|
Is Counter Party a Related Party According to CMB Regulations?
Hayır (No)
oda_RelationWithCounterPartyIfAny|http://www.xbrl.org/2003/role/verboseLabel
Relation with Counter Party if any
None.
oda_AgreementSigningDateIfExists|
Agreement Signing Date if Exists
02/11/2021
oda_ValueDeterminationMethodOfNoncurrentFinancialAsset|
Value Determination Method of Non-current Financial Asset
It is determined according to the Partnership Agreement amended on 31.10.2017.
oda_DidValuationReportBePrepared|
Did Valuation Report be Prepared?
Düzenlenmedi (Not Prepared)
oda_ReasonForNotPreparingValuationReportIfItWasNotPrepared|
Reason for not Preparing Valuation Report if it was not Prepared
It is determined according to the Partnership Agreement amended on 31.10.2017.
oda_DateAndNumberOfValuationReport|
Date and Number of Valuation Report
-
oda_TitleOfValuationCompanyPreparedReport|
Title of Valuation Company Prepared Report
-
oda_ValueDeterminedInValuationReportIfExists|
Value Determined in Valuation Report if Exists
-
oda_ReasonsIfTransactionWasntWillNotBePerformedInAccordanceWithValuationReport|
Reasons if Transaction wasn't/will not be performed in Accordance with Valuation Report
-
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

(*)The Euro sale price is calculated using today's Central Bank Foreign Exchange purchase rate.

As stated in the material event disclosures dated 18 August 2017, 31 October 2017 and 27 October 2020; within the scope of the "Amendment Protocol", which was prepared to amend the "Partnership Agreement" signed by the partners of the Company's joint venture Eczacıbaşı-Monrol and entered into force on 31.10.2017;

-      After the capital increase of Eczacıbaşı-Monrol, 84% of Eczacıbaşı-Monrol's capital was transferred to Eczacıbaşı Group (83.996% to the Company, 0.002% to Eczacıbaşı Holding A.Ş. and 0.002% to EİP Eczacıbaşı İlaç Pazarlama A.Ş.) and 16% belongs to Bozlu Group (Şükrü Bozluolçay and Uğur Bozluolçay) as of 31.10.2017.

-      Eczacıbaşı Group undertook to sell Eczacıbaşı-Monrol's shares corresponding to 9% of the capital of Eczacıbaşı-Monrol to Bozlu Group (which will increase the partnership rate at Eczacıbaşı-Monrol to 25%) within 5 years from the date of general assembly registration (registered on 03.11.2017); Bozlu Group, on the other hand, undertook to purchase the shares corresponding to 9% of Eczacıbaşı-Monrol's capital from Eczacıbaşı Group within 5 years from the registration date of the General Assembly.

-      Within the framework of the "commitment" specified in the Amendment Protocol, in the first phase shares corresponding to 3% of Eczacıbaşı-Monrol's share capital has been sold to Bozlu Group on 27 October 2020 and as a result 81% of Eczacıbaşı-Monrol's share capital was owned by our Company whereby 19% thereof is owned by Bozlu Group.

-      For the purposes of completion of the second phase within the scope of the "commitment" in the Amendment Protocol, upon request of Bozlu Group, share transfer agreement dated 2 November 2021 has been executed by and between our Company and Bozlu Group for the transfer shares in the amount of 2,025,000 corresponding to 3% of the share capital of Eczacıbaşı-Monrol.

-      Pursuant to the share transfer agreement dated 2 November 2021; our Company, has sold and transferred its shares in the amount of 2,025,000 corresponding to 3% of the share capital of Eczacıbaşı-Monrol to Bozlu Group in consideration of a purchase price calculated in accordance with the provisions of Amendment Protocol which is in total EUR 907,113.29.

After the sale, 78% of Eczacıbaşı-Monrol's capital belonged to the Company and 22% to the Bozlu Group. After the share transfer, there has been no change in the current board member structure of Eczacıbaşı-Monrol.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.